Table of Contents
1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. Global Clinical Trial Supplies Market Insights
3.1. Industry Value Chain Analysis
3.1.1. DROC Analysis
3.1.2. Growth Drivers
3.1.2.1. Increasing Pharmaceutical and Biopharmaceutical R&D Expenditures
3.1.2.2. Rising Burden of Chronic and Communicable Diseases
3.1.3. Restraints
3.1.3.1. Adverse Drug Reactions
3.1.4. Opportunities
3.1.4.1. Rising New Drug Development Trial in Emerging Countries
3.1.5. Challenges
3.1.5.1. Impact of COVID-19 on Supply Chain
3.2. Technology Advancements/Recent Developments
3.3. Regulatory Framework
3.4. Porter's Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of New Entrants
3.4.4. Threat of Substitutes
3.4.5. Intensity of Rivalry
4. Global Clinical Trial Supplies Market Overview
4.1. Market Size & Forecast, 2019-2029
4.1.1. By Value (USD Million)
4.2. Market Share & Forecast
4.2.1. By Product
4.2.1.1. Manufacturing
4.2.1.2. Supply Chain Management
4.2.1.3. Logistics
4.2.1.4. Storage & Distribution
4.2.1.5. Others
4.2.2. By Clinical Phase
4.2.2.1. Phase I
4.2.2.2. Phase II
4.2.2.3. Phase III
4.2.2.4. Others
4.2.3. By Therapeutic use
4.2.3.1. Oncology
4.2.3.2. CNS
4.2.3.3. Cardiovascular
4.2.3.4. Infectious Disease
4.2.3.5. Metabolic Disorders
4.2.3.6. Others
4.2.4. By End Use
4.2.4.1. Pharmaceutical
4.2.4.2. Biologics
4.2.4.3. Medical Device
4.2.4.4. Others
4.2.5. By Region
4.2.5.1. North America
4.2.5.2. Europe
4.2.5.3. Asia Pacific (APAC)
4.2.5.4. Latin America
4.2.5.5. Middle East and Africa (MEA)
5. North America Clinical Trial Supplies Market
5.1. Market Size & Forecast, 2019-2029
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Product
5.2.2. By Clinical Phase
5.2.3. By Therapeutic use
5.2.4. By End Use
5.2.5. By Country
5.2.5.1. US
5.2.5.1.1. By Product
5.2.5.1.2. By Clinical Phase
5.2.5.1.3. By Therapeutic use
5.2.5.1.4. By End Use
5.2.5.2. Canada
5.2.5.2.1. By Product
5.2.5.2.2. By Clinical Phase
5.2.5.2.3. By Therapeutic use
5.2.5.2.4. By End Use
6. Europe Clinical Trial Supplies Market
6.1. Market Size & Forecast, 2019-2029
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Clinical Phase
6.2.3. By Therapeutic use
6.2.4. By End Use
6.2.5. By Country
6.2.5.1. Germany
6.2.5.1.1. By Product
6.2.5.1.2. By Clinical Phase
6.2.5.1.3. By Therapeutic use
6.2.5.1.4. By End Use
6.2.5.2. UK
6.2.5.2.1. By Product
6.2.5.2.2. By Clinical Phase
6.2.5.2.3. By Therapeutic use
6.2.5.2.4. By End Use
6.2.5.3. Italy
6.2.5.3.1. By Product
6.2.5.3.2. By Clinical Phase
6.2.5.3.3. By Therapeutic use
6.2.5.3.4. By End Use
6.2.5.4. France
6.2.5.4.1. By Product
6.2.5.4.2. By Clinical Phase
6.2.5.4.3. By Therapeutic use
6.2.5.4.4. By End Use
6.2.5.5. Spain
6.2.5.5.1. By Product
6.2.5.5.2. By Clinical Phase
6.2.5.5.3. By Therapeutic use
6.2.5.5.4. By End Use
6.2.5.6. The Netherlands
6.2.5.6.1. By Product
6.2.5.6.2. By Clinical Phase
6.2.5.6.3. By Therapeutic use
6.2.5.6.4. By End Use
6.2.5.7. Rest of Europe
6.2.5.7.1. By Product
6.2.5.7.2. By Clinical Phase
6.2.5.7.3. By Therapeutic use
6.2.5.7.4. By End Use
7. Asia-Pacific Clinical Trial Supplies Market
7.1. Market Size & Forecast, 2019-2029
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Clinical Phase
7.2.3. By Therapeutic use
7.2.4. By End Use
7.2.5. By Country
7.2.5.1. China
7.2.5.1.1. By Product
7.2.5.1.2. By Clinical Phase
7.2.5.1.3. By Therapeutic use
7.2.5.1.4. By End Use
7.2.5.2. India
7.2.5.2.1. By Product
7.2.5.2.2. By Clinical Phase
7.2.5.2.3. By Therapeutic use
7.2.5.2.4. By End Use
7.2.5.3. Japan
7.2.5.3.1. By Product
7.2.5.3.2. By Clinical Phase
7.2.5.3.3. By Therapeutic use
7.2.5.3.4. By End Use
7.2.5.4. South Korea
7.2.5.4.1. By Product
7.2.5.4.2. By Clinical Phase
7.2.5.4.3. By Therapeutic use
7.2.5.4.4. By End Use
7.2.5.5. Australia & New Zealand
7.2.5.5.1. By Product
7.2.5.5.2. By Clinical Phase
7.2.5.5.3. By Therapeutic use
7.2.5.5.4. By End Use
7.2.5.6. Indonesia
7.2.5.6.1. By Product
7.2.5.6.2. By Clinical Phase
7.2.5.6.3. By Therapeutic use
7.2.5.6.4. By End Use
7.2.5.7. Malaysia
7.2.5.7.1. By Product
7.2.5.7.2. By Clinical Phase
7.2.5.7.3. By Therapeutic use
7.2.5.7.4. By End Use
7.2.5.8. Singapore
7.2.5.8.1. By Product
7.2.5.8.2. By Clinical Phase
7.2.5.8.3. By Therapeutic use
7.2.5.8.4. By End Use
7.2.5.9. Philippines
7.2.5.9.1. By Product
7.2.5.9.2. By Clinical Phase
7.2.5.9.3. By Therapeutic use
7.2.5.9.4. By End Use
7.2.5.10. Vietnam
7.2.5.10.1. By Product
7.2.5.10.2. By Clinical Phase
7.2.5.10.3. By Therapeutic use
7.2.5.10.4. By End Use
7.2.5.11. Rest of APAC
7.2.5.11.1. By Product
7.2.5.11.2. By Clinical Phase
7.2.5.11.3. By Therapeutic use
7.2.5.11.4. By End Use
8. Latin America Clinical Trial Supplies Market
8.1. Market Size & Forecast, 2019-2029
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Clinical Phase
8.2.3. By Therapeutic use
8.2.4. By End Use
8.2.5. By Country
8.2.5.1. Brazil
8.2.5.1.1. By Product
8.2.5.1.2. By Clinical Phase
8.2.5.1.3. By Therapeutic use
8.2.5.1.4. By End Use
8.2.5.2. Mexico
8.2.5.2.1. By Product
8.2.5.2.2. By Clinical Phase
8.2.5.2.3. By Therapeutic use
8.2.5.2.4. By End Use
8.2.5.3. Argentina
8.2.5.3.1. By Product
8.2.5.3.2. By Clinical Phase
8.2.5.3.3. By Therapeutic use
8.2.5.3.4. By End Use
8.2.5.4. Peru
8.2.5.4.1. By Product
8.2.5.4.2. By Clinical Phase
8.2.5.4.3. By Therapeutic use
8.2.5.4.4. By End Use
8.2.5.5. Rest of LATAM
8.2.5.5.1. By Product
8.2.5.5.2. By Clinical Phase
8.2.5.5.3. By Therapeutic use
8.2.5.5.4. By End Use
9. Middle East & Africa Clinical Trial Supplies Market
9.1. Market Size & Forecast, 2019-2029
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Clinical Phase
9.2.3. By Therapeutic use
9.2.4. By End Use
9.2.5. By Country
9.2.5.1. Saudi Arabia
9.2.5.1.1. By Product
9.2.5.1.2. By Clinical Phase
9.2.5.1.3. By Therapeutic use
9.2.5.1.4. By End Use
9.2.5.2. UAE
9.2.5.2.1. By Product
9.2.5.2.2. By Clinical Phase
9.2.5.2.3. By Therapeutic use
9.2.5.2.4. By End Use
9.2.5.3. Qatar
9.2.5.3.1. By Product
9.2.5.3.2. By Clinical Phase
9.2.5.3.3. By Therapeutic use
9.2.5.3.4. By End Use
9.2.5.4. Kuwait
9.2.5.4.1. By Product
9.2.5.4.2. By Clinical Phase
9.2.5.4.3. By Therapeutic use
9.2.5.4.4. By End Use
9.2.5.5. South Africa
9.2.5.5.1. By Product
9.2.5.5.2. By Clinical Phase
9.2.5.5.3. By Therapeutic use
9.2.5.5.4. By End Use
9.2.5.6. Nigeria
9.2.5.6.1. By Product
9.2.5.6.2. By Clinical Phase
9.2.5.6.3. By Therapeutic use
9.2.5.6.4. By End Use
9.2.5.7. Algeria
9.2.5.7.1. By Product
9.2.5.7.2. By Clinical Phase
9.2.5.7.3. By Therapeutic use
9.2.5.7.4. By End Use
9.2.5.8. Rest of MEA
9.2.5.8.1. By Product
9.2.5.8.2. By Clinical Phase
9.2.5.8.3. By Therapeutic use
9.2.5.8.4. By End Use
10. Competitive Landscape
10.1. List of Key Players and Their Offerings
10.2. Global Clinical Trial Supplies Company Market Share Analysis, 2022
10.3. Competitive Benchmarking, By Operating Parameters
10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
11. Impact of Covid-19 on Global Clinical Trial Supplies Market
12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
12.1. Alamc Group
12.2. Catalent, Inc.
12.3. PCI Services
12.4. Parexel International Corporation
12.5. Sharp Packaging Services
12.6. Biocair
12.7. O&M Movianto
12.8. KLIFO A/S
12.9. Thermo Fisher Scientific, Inc.
12.10. Movianto
12.11. Sharp
12.12. Catalent, Inc
12.13. Bionical Ltd.
12.14. Alium Medical Limited
12.15. Other Prominent Players
13. Key Strategic Recommendations
14. Research Methodology
14.1. Qualitative Research
14.1.1. Primary & Secondary Research
14.2. Quantitative Research
14.3. Market Breakdown & Data Triangulation
14.3.1. Secondary Research
14.3.2. Primary Research
14.4. Breakdown of Primary Research Respondents, By Region
14.5. Assumptions & Limitations